Inhaled tiotropium bromide and risk of stroke

British Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2009, Pages 731-736

  Grosso, Anthony ^a,b   Douglas, Ian ^c   Hingorani, Aroon D ^b   MacAllister, Raymond ^b   Hubbard, Richard ^d   Smeeth, Liam ^c  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anti cholinergics; Drug safety; Ipratropium; Stroke; Tiotroprium

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DATA BASE; DRUG SAFETY; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; UNITED STATES;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; GREAT BRITAIN; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; RISK FACTORS; SCOPOLAMINE DERIVATIVES; STROKE;

EID: 70449331317     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03517.x     Document Type: Article

References (14)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008 371 : 1612 1623.
2. US Food and Drug Administration. Early communication about an ongoing safety review of tiotropium (marketed as Spiriva HandiHaler). Available at http://www.fda.gov/cder/drug/early-comm/tiotropium.htm (last accessed 20 July 2008).
3. Spiriva HandiHaler (tiotropium bromide) Summary of Product Characteristics. Boehringer Ingelheim. Available at http://emc.medicines.org.uk/ emc/industry/default.asp?page=displaydoc.asp&documentid=10039 (last accessed 20 August 2008).
4. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008 359 : 1543 1554.
5. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 300 : 1439 1450.
6. Whitaker H. The self controlled case series method. BMJ 2008 337 : a1069.
7. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008 66 : 689 694.
8. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008 337 : a1227.
9. Hubbard R, Lewis S, West J, Smith C, Godfrey C, Smeeth L, Farrington P, Britton J. Bupropion and the risk of sudden death: a self-controlled case-series analysis using The Health Improvement Network. Thorax 2005 60 : 848 850.
10. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008 3 : 163 169.
11. General practice research database. Available at http://www.gprd.com/ home/ (last accessed 25 March 2008).
12. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics 1995 51 : 228 235.
13. Powrie DJ, Wilkinson TM, Donaldson GC, Jones P, Scrine K, Viel K, Kesten S, Wedzicha JA. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007 30 : 472 478.
14. Boekholdt SM, Peters RJ, Hack CE, Day NE, Luben R, Bingham SA, Wareham NJ, Reitsma PH, Khaw KT. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol 2004 24 : 1503 1508.